Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets


share with twitter share with LinkedIn share with facebook
share via e-mail
09/07/2017 | 09:43am CET
ABLYNX TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON GHENT, Belgium, 7 September 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announces that it will participate in the following upcoming investor conferences taking place in London, UK:
  • J.P. Morgan's London Small/Mid Cap Conference: one-on-one meetings with institutional investors are scheduled for Thursday 14 September 2017.
  • Bank of America Merrill Lynch (BAML) Global Healthcare Conference: a presentation is scheduled for Friday 15 September 2017 at 01.45 p.m. GMT (02.45 p.m. Central European Time), followed by a breakout session, together with one-on-one meetings with institutional investors. The slides will be available, shortly after the presentation is given, on the Company's website, under the News & Events section.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact: Ablynx

Dr Edwin Moses CEO

t: +32 (0)9 262 00 07

m: +32 (0)473 39 50 68

e: [email protected]

Lies Vanneste Director IR

t: +32 (0)9 262 0137

m: +32 (0)498 05 35 79

e: [email protected]


Ablynx media relations: Consilium Strategic Communications

Mary-Jane Elliott, Philippa Gardner, Sukaina Virji t: +44 (0)20 3709 5700

e: [email protected]


Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any an ticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be tak en as a representation that such trends or activities will continue in the future. As a result, the Company expressly dis claims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forwa rd-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such p erson's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does eitheraccept any responsibility forthe future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Ablynx NV published this content on 07 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 07 September 2017 07:42:04 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABLYNX
12/12 ABLYNX : 12/12/2017 ablynx reports additional clinically important benefits of c..
12/12 ABLYNX : Reports additional clinically important benefits of caplacizumab from i..
12/07 ABLYNX : Will host a webcast to discuss additional data from its phase iii hercu..
11/29 ABLYNX : 29/11/2017 publication in accordance with article 14 of the belgian law..
11/29 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/21 ABLYNX : 21/11/2017 results from the phase iii hercules study of caplacizumab fo..
11/21 ABLYNX : Results from the phase iii hercules study of caplacizumab for the treat..
11/16 ABLYNX : 16/11/2017 ablynx announces results for the first nine months of 2017 a..
11/16 ABLYNX : Announces results for the first nine months of 2017 and a year-to-date ..
11/15 ABLYNX : 15/11/2017 publication in accordance with article 14 of the belgian law..
More news
News from SeekingAlpha
12/07 Ablynx to update on Phase 3 study of caplacizumab December 12
11/16 Ablynx NV reports 9M results
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/17 Ablynx prices $175M U.S. IPO at $20.95
10/04 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 4, 2017
Financials (€)
Sales 2017 64,7 M
EBIT 2017 -56,2 M
Net income 2017 -73,4 M
Finance 2017 203 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 20,4x
EV / Sales 2018 23,6x
Capitalization 1 524 M
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 23,6 €
Spread / Average Target 16%
EPS Revisions
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX86.59%1 802
CELLTRION, INC.--.--%23 699
LONZA GROUP57.44%20 102